MicroRNA as therapeutic targets for treatment of depression
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Depression is a potentially life-threatening mental disorder affecting approximately 300 million people worldwide. Despite much effort, the molecular underpinnings of clinical depression remain poorly defined, and current treatments carry limited therapeutic efficacy and potentially burdensome side effects. Recently, small noncoding RNA molecules known as microRNA (miRNA) have gained prominence as a target for therapeutic intervention, given their capacity to regulate neuronal physiology. Further, mounting evidence suggests a prominent role for miRNA in depressive molecular signaling. Recent studies have demonstrated that dysregulation of miRNA expression occurs in animal models of depression, and in the post-mortem tissue of clinically depressed patients. Investigations into depression-associated miRNA disruption reveals dramatic effects on downstream targets, many of which are thought to contribute to depressive symptoms. Furthermore, selective serotonin reuptake inhibitors, as well as other antidepressant drugs, have the capacity to reverse aberrant depressive miRNA expression and their downstream targets. Given the powerful effects that miRNA have on the central nervous system transcriptome, and the aforementioned studies, there is a compelling rationale to begin to assess the potential contribution of miRNA to depressive etiology. Here, we review the molecular biology of miRNA, our current understanding of miRNA in relation to clinical depression, and the utility of targeting miRNA for antidepressant treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
miRBase: integrating microRNA annotation and deep-sequencing data
Kozomara, A., & Griffiths-Jones, S. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1027 · Cited by 3,634
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
MicroRNAs Regulate Brain Morphogenesis in Zebrafish
Giraldez, A. J., Cinalli, R. M., Glasner, M. E., Enright, A. J., Thomson, J. M., Baskerville, S., Hammond, S. M., Bartel, D. P., & Schier, A. F. (2005) · Science · doi:10.1126/science.1109020 · Cited by 1,315
Sen, S., Duman, R., & Sanacora, G. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.005 · Cited by 1,232
Untreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180 · cited 1×
“12–15 Dysregulation of structural plasticity, synaptic connectivity, and dendritic morphology are thought to contribute to depressive pathophysiology.”
Increased hippocampal bdnf immunoreactivity in subjects treated with antidepressant medication
Chen, B., Dowlatshahi, D., MacQueen, G. M., Wang, J.-F., & Young, L. T. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01083-6 · Cited by 1,164
Li, N., Liu, R.-J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.015 · Cited by 1,082
Andrade, L., Caraveo‐anduaga, J. J., Berglund, P., Bijl, R. V., Graaf, R. D., Vollebergh, W., Dragomirecka, E., Kohn, R., Keller, M., Kessler, R. C., et al. (2003) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.138 · Cited by 1,068
MicroRNAs 103 and 107 regulate insulin sensitivity
Trajkovski, M., Hausser, J., Soutschek, J., Bhat, B., Akin, A., Zavolan, M., Heim, M. H., & Stoffel, M. (2011) · Nature · doi:10.1038/nature10112 · Cited by 1,000 · cited 1×
“As such, antagomirs (cholesterol-conjugated 2-O-methyl RNA antisense oligonucleotides) are currently being used to target aberrant miRNA expression in a range of disease models.(123,127,128) Conversely, impairment of miRNA expression leads to excessive translation of target mRNA,”
Adult brain neurogenesis and psychiatry: a novel theory of depression
Jacobs, B. L., van Praag, H., & Gage, F. H. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000712 · Cited by 964
Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., Kelnar, K., Kemppainen, J., Brown, D., Chen, C., et al. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14103 · Cited by 943
Kempton, M. J., Salvador, Z., Munafò, M. R., Geddes, J. R., Simmons, A., Frangou, S., & Williams, S. C. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.60 · Cited by 886
Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides
Rayner, K. J., Esau, C. C., Hussain, F. N., McDaniel, A. L., Marshall, S. M., van Gils, J. M., Ray, T. D., Sheedy, F. J., Goedeke, L., Liu, X., et al. (2011) · Nature · doi:10.1038/nature10486 · Cited by 706 · cited 1×
“As such, antagomirs (cholesterol-conjugated 2-O-methyl RNA antisense oligonucleotides) are currently being used to target aberrant miRNA expression in a range of disease models.(123,127,128) Conversely, impairment of miRNA expression leads to excessive translation of target mRNA,”
Perkins, D. O., Jeffries, C. D., Jarskog, L. F., Thomson, J. M., Woods, K., Newman, M. A., Parker, J. S., Jin, J., & Hammond, S. M. (2007) · Genome Biology · doi:10.1186/gb-2007-8-2-r27 · Cited by 574 · cited 1×
“known tumor suppressor (via inhibition of cell growth) and is also associated with the development of schizophrenia.(76,77) In”
An activity-regulated microRNA controls dendritic plasticity by down-regulating p250GAP
Wayman, G. A., Davare, M., Ando, H., Fortin, D., Varlamova, O., Cheng, H.-Y. M., Marks, D., Obrietan, K., Soderling, T. R., Goodman, R. H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803072105 · Cited by 559 · cited 1×
“103 miR-132 is also induced by light within the SCN, regulating the expression of the per1 ( Period circadian protein homolog 1 ) clock gene and modulating the capacity of light to entrain circadian rhythmicity.”
Self-citationArnone, D., McIntosh, A. M., Ebmeier, K. P., Munafò, M. R., & Anderson, I. M. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.05.003 · Cited by 495
MiR-16 Targets the Serotonin Transporter: A New Facet for Adaptive Responses to Antidepressants
Baudry, A., Mouillet-Richard, S., Schneider, B., Launay, J.-M., & Kellermann, O. (2010) · Science · doi:10.1126/science.1193692 · Cited by 480
Conditional Loss of Dicer Disrupts Cellular and Tissue Morphogenesis in the Cortex and Hippocampus
Davis, T. H., Cuellar, T. L., Koch, S. M., Barker, A. J., Harfe, B. D., McManus, M. T., & Ullian, E. M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4815-07.2008 · Cited by 447
Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA
Klein, M. E., Lioy, D. T., Ma, L., Impey, S., Mandel, G., & Goodman, R. H. (2007) · Nature Neuroscience · doi:10.1038/nn2010 · Cited by 444 · cited 1×
“tory pathways, indicates the importance of careful dosing of any miRNA-associated therapeutics.(67,97) miRNA may have a buffered effect on downstream targets such that minor changes in miRNA expression therapeutically hone signaling pathways, but yield massive dysregulation if expressed beyond a threshold of tolerance.”
Rajasethupathy, P., Fiumara, F., Sheridan, R., Betel, D., Puthanveettil, S. V., Russo, J. J., Sander, C., Tuschl, T., & Kandel, E. (2009) · Neuron · doi:10.1016/j.neuron.2009.05.029 · Cited by 406
Depression: an inflammatory illness?: Figure 1
Krishnadas, R., & Cavanagh, J. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301779 · Cited by 392 · cited 1×
“Further, there is increasing evidence for a neuroimmune and microglial component to depressive pathophysiology.(41) In line with this idea, depressive symptoms are closely associated with the behavioral effects associated with systemic infection, and expression of cytokines such as interleukin (IL)-1, IL-6, and tumor…”
Gray, S. J., Nagabhushan Kalburgi, S., McCown, T. J., & Jude Samulski, R. (2013) · Gene Therapy · doi:10.1038/gt.2012.101 · Cited by 377
Synaptic plasticity and mood disorders
Duman, R. S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001016 · Cited by 363 · cited 1×
“is of particular interest in understanding the molecular etiology of depression, and has led to the development of a neurotrophic hypothesis of depression.(23) BDNF within the amygdala and the anterior cingulate cortex is protective against the depression-associated polymorphisms of the serotonin transporter.”
Cytokines and Glucocorticoid Receptor Signaling
Pace, T. W. W., & Miller, A. H. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04984.x · Cited by 339
Uchida, S., Hara, K., Kobayashi, A., Funato, H., Hobara, T., Otsuki, K., Yamagata, H., McEwen, B. S., & Watanabe, Y. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1436-10.2010 · Cited by 310
Adeno-Associated Virus Serotype 9 Transduction in the Central Nervous System of Nonhuman Primates
Samaranch, L., Salegio, E. A., San Sebastian, W., Kells, A. P., Foust, K. D., Bringas, J. R., Lamarre, C., Forsayeth, J., Kaspar, B. K., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.200 · Cited by 299 · cited 1×
“137 Moreover, integration of viral-vector technology with the use of cell-type specific promoters could prove useful given the brain-region specific nature of molecular dysregulation in clinical depression (and indeed of miRNA themselves).”
Kim, A. H., Reimers, M., Maher, B., Williamson, V., McMichael, O., McClay, J. L., van den Oord, E. J. C. G., Riley, B. P., Kendler, K. S., & Vladimirov, V. I. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.002 · Cited by 298 · cited 1×
“Some global expression profiling of neuronal miRNA expression has been performed in the context of bipolar disorder, revealing several key alterations in miRNA expression.(80,81) However, similar studies in major depression patients are only in their earliest stages.”
Gourley, S. L., Wu, F. J., Kiraly, D. D., Ploski, J. E., Kedves, A. T., Duman, R. S., & Taylor, J. R. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.07.016 · Cited by 287
Moreau, M. P., Bruse, S. E., David-Rus, R., Buyske, S., & Brzustowicz, L. M. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.039 · Cited by 279
Mellios, N., Huang, H.-S., Grigorenko, A., Rogaev, E., & Akbarian, S. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn201 · Cited by 274
An activity-induced microRNA controls dendritic spine formation by regulating Rac1-PAK signaling
Impey, S., Davare, M., Lasiek, A., Fortin, D., Ando, H., Varlamova, O., Obrietan, K., Soderling, T. R., Goodman, R. H., & Wayman, G. A. (2010) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2009.10.005 · Cited by 270
Self-citationSynaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness
Honer, W. G., Falkai, P., Chen, C., Arango, V., Mann, J. J., & Dwork, A. J. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00679-4 · Cited by 244 · cited 1×
“connectivity, and dendritic morphology are thought to contribute to depressive pathophysiology.(16,17) Deficits in neuro-”
Blood microRNA changes in depressed patients during antidepressant treatment
Bocchio-Chiavetto, L., Maffioletti, E., Bettinsoli, P., Giovannini, C., Bignotti, S., Tardito, D., Corrada, D., Milanesi, L., & Gennarelli, M. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.06.013 · Cited by 238 · cited 1×
“However, similar studies in major depression patients are only in their earliest stages.(82,83) Hence, more such studies would provide needed insight into the differential expression of miRNA in patients with clinical depression.”
Early Second-Trimester Serum MiRNA Profiling Predicts Gestational Diabetes Mellitus
Zhao, C., Dong, J., Jiang, T., Shi, Z., Yu, B., Zhu, Y., Chen, D., Xu, J., Huo, R., Dai, J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023925 · Cited by 230
Uchida, S., Nishida, A., Hara, K., Kamemoto, T., Suetsugi, M., Fujimoto, M., Watanuki, T., Wakabayashi, Y., Otsuki, K., McEwen, B. S., et al. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06218.x · Cited by 203
Saus, E., Soria, V., Escaramís, G., Vivarelli, F., Crespo, J. M., Kagerbauer, B., Menchón, J. M., Urretavizcaya, M., Gratacòs, M., & Estivill, X. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq316 · Cited by 163 · cited 2×
“miR-182 is predicted to target the circadian regulatory gene, Clock, and exhibits diurnal oscillation within the retina.(106,108) Thus, miRNA may modulate the depressive effect of circadian disruption and could serve as therapeutic targets to restore normal sleep patterns and stabilize mood.”
Dwivedi, Y., Rizavi, H. S., Zhang, H., Roberts, R. C., Conley, R. R., & Pandey, G. N. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990575 · Cited by 101
Xu, Y., Liu, H., Li, F., Sun, N., Ren, Y., Liu, Z., Cao, X., Wang, Y., Liu, P., & Zhang, K. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.05.019 · Cited by 99 · cited 1×
“A polymorphism within miR-30e is positively correlated with depression and its symptomatic onset.(75) miR-30e is a”
Oved, K., Morag, A., Pasmanik-Chor, M., Oron-Karni, V., Shomron, N., Rehavi, M., Stingl, J. C., & Gurwitz, D. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.93 · Cited by 66 · cited 1×
“However, similar studies in major depression patients are only in their earliest stages.(82,83) Hence, more such studies would provide needed insight into the differential expression of miRNA in patients with clinical depression.”
Genetic Variations in MicroRNA Processing Genes Are Associated with Susceptibility in Depression
He, Y., Zhou, Y., Xi, Q., Cui, H., Luo, T., Song, H., Nie, X., Wang, L., & Ying, B. (2012) · DNA and Cell Biology · doi:10.1089/dna.2012.1660 · Cited by 52 · cited 1×
“remain largely intact, some mutations in genes required for miRNA processing have been found.(129) Further, mutations”
Cited by
Brand, S., Moller, M., & Harvey, B. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150307004545 · Cited by 95
Fang, Y., Qiu, Q., Zhang, S., Sun, L., Li, G., Xiao, S., & Li, X. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.11.090 · Cited by 90
Sun, N., Lei, L., Wang, Y., Yang, C., Liu, Z., Li, X., & Zhang, K. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.01.017 · Cited by 74
Yang, X., Yang, Q., Wang, X., Luo, C., Wan, Y., Li, J., Liu, K., Zhou, M., & Zhang, C. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-014-8312-z · Cited by 69
Patrício, P., Mateus-Pinheiro, A., Irmler, M., Alves, N. D., Machado-Santos, A. R., Morais, M., Correia, J. S., Korostynski, M., Piechota, M., Stoffel, R., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.176 · Cited by 57
“This finding is interesting in light of the role of miRNAs in neuronal development and neuroplasticity (McClung and Nestler, 2008) and their potential for serving as new therapeutic targets (Hansen and Obrietan, 2013).”
Background
Metadata
- Authors
- Obrietan, K., & Hansen, K.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2013-07
- Volume
- 9
- Pages
- 1011
- ISSN
- 1176-6328 (ISSN-L)
- OpenAlex
- W1969124961
- Cited by
- 53
- References
- 41
- FWCI
- 1.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.